BillionToOne, Inc. (BLLN)

Market Cap	4.06B
Revenue (ttm)	254.14M
Net Income (ttm)	-11.09M
Shares Out	45.77M
EPS (ttm)	-1.07
PE Ratio	n/a
Forward PE	145.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	622,337
Open	95.00
Previous Close	94.72
Day's Range	85.53 - 95.35
52-Week Range	80.51 - 138.70
Beta	n/a
Analysts	Buy
Price Target	137.83 (+55.34%)
Earnings Date	Dec 9, 2025

About BLLN

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and type...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 6, 2025
• Employees: 620
• Stock Exchange: NASDAQ
• Ticker Symbol: BLLN
• Website: https://www.billiontoone.com

Financial Performance

Financial numbers in USD

Analyst Summary

According to 6 analysts, the average rating for BLLN stock is "Buy." The 12-month stock price target is $137.83, which is an increase of 55.34% from the latest price.

Price Target

$137.83

(55.34% upside)

Analyst Consensus: Buy